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Objective: To investigate the expression of OPG, RANKL and TRAP during alveolar healing
process (7, 14, 21, 28 and 42 postoperative days) in ovariectomized rats treated with
raloxifene or with oestrogen replacement therapy, using immunohistochemistry reaction
approach.
Materials and methods: Wistar female rats (10 weeks age) were submitted to ovariectomy
surgery (OVX) or sham surgery. The female rats were divided in four groups: (1) sham; (2)
OVX/O (ovariectomy and oil); (3) OVX/E2 (ovariectomy and oestrogen replacement); (4) OVX/
RLX (ovariectomy and raloxifene therapy).
Results: It was observed high amount of OPG immunolabelling with predominance at 14 and
21 postoperative days on sham and OVX/RLX groups, respectively. At 7 postoperative days,
there was no difference between the groups for TRAP protein. Otherwise, to the other
periods, it was observed greater expression of TRAP and RANKL protein on OVX/O group
compared to sham, OVX/E2 and OVX/RLX groups. It was also observed a discrete TRAP
immunolabelling at 28 and 42 postoperative days on OVX/RLX group.
Conclusions: Oestrogen deficiency induces osteoclastogenesis in the alveolar healing pro-
cess. Quantitative changes in the osteoclastic activity could be prevented through the
raloxifene therapy.
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Raloxifene (benzotiofen analogue) is a selective modulator of
oestrogen receptors (SERMs) that prevents bone loss. The
medicament is used in the treatment and prevention of
osteoporosis in the United States and in many other
countries, due to its selective activity to the oestrogen
receptors of the bone tissue. According to the literature,
raloxifene reduces the expression of bone turnover markers,
increases bone mineral density, reduces vertebral fractures
risk from 50% to 30% in precocious menopause women,1* Corresponding author.
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Open access under the Elsevier OA license.decreases the breast cancer incidence2 and changes the lipids
concentration in the bloodstream.3 However, the mechan-
isms whereby this compound modulates bone cells activities
are less known.
Selective markers of bone turnover as osteoprotegerin
(OPG), Kappa B factor ligand of the tumoural necrosis factor
(RANKL) and tartrate resistant acid phosphatase (TRAP) are
used for analysis of the effects of pharmacological agents and
pathogenesis of bone diseases in ovariectomized rat model
(OVX). These markers have been considered relatively specific
for osteoblasts (OPG and RANKL)4,5 and osteoclasts (TRAP).6,7taokamoto@usc.br (R. Okamoto).
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raloxifene therapy with oestrogen replacement therapy in
ovariectomized rats during the chronology of the alveolar
healing process. To better understand the potential of
raloxifene in improving bone quality a semi-quantitative
evaluation of the osteoclastogenesis during the alveolar
healing process were proceeded by means of immunohis-
tochemistry reactions of OPG, RANKL and TRAP protein.
2. Material and methods
2.1. Animals
Laboratory principals of animal care8 and the national laws of
the animal use were followed in the present study that was
authorized by the Ethics Committee in animal experimenta-
tion of the Sa˜o Paulo State University, Brazil. One hundred and
sixty female Wistar rats (10 weeks age) were kept in the
adequate place (22  2 8C, 12 h light/12 h dark), with food and
water ad libitum.
Rats with regular estrous cycle were submitted to ovari-
ectomy (OVX)9 or sham surgery under xilazine (0.03 ml/
100 g bw/ip-Dopaser Laboratories Calier S.A., Barcelona,
Spain) and ketamin (0.07 ml/100 g bw/ip-Fort Dodge Sau´ de
Animal Ltd., Brazil). The animals were randomly separated in
4 groups with 40 animals each one: (1) sham, (2) OVX/O, (3)
OVX/E2 and (4) OVX/RLX. Every treatment started at the 8th
day after ovariectomy and lasted for 60 days.
2.2. Treatment
The OVX animals received pellets (1.2 cm silastic tubing; Dow
Corning, Grand Rapids, MI, USA) with 17b-estradiol (400 mg;
Sigma, Saint Louis, MO, USA) – OVX/E2 group or pellets with
corn oil – group OVX/O. The pellets were subcutaneously
inserted in the back of the rats and changed each 30 days
during the experimental period because in this last period
there was modification in the vaginal smears with the
presence of large amounts of leukocytes, according to
previous studies conducted in our laboratory (date not
shown). Raloxifene (1 mg/kg/day; Evista; Lilly, Sa˜o Paulo,
SP, Brazil) was directly liberated in the stomach of the
experimental animals, through gavage. The treatments were
performed for 60 days.
2.3. Dental extraction
The animals were anesthetized with xylazine (0.03 ml/100 g
body weight [bw]/intraperitoneal [ip]; Dopaser1 Laboratories
Calier SA, Barcelona, Spain) and ketamine (7 ml/kg bw/ip; Fort
Dodge Sau´ de Animal Ltd., Brazil), and after the antisepsis
(polyvinylpyrrolidone iodide; Indu´ stria Quı´mica e Farmaceˆu-
tica Rioquı´mica Ltd., Brazil), the right upper incisive was
extracted with appropriate instrumental.10 The dental sockets
were sutured with silk thread (Ethicon 4.0, Johnson and
Johnson, Sa˜o Paulo, SP, Brazil). The extractions were realized
in a way that at the end of 60 days, it was possible to obtain
pieces with reference to 7, 14, 21, 28 and 42 days of alveolar
wound healing.2.4. Collection of materials
After 60 days, the animals were sacrificed by intracardic
perfusion (Cole Parmer Instrument Company, Vernon Hills,
IL, USA) with a 4% paraformaldehyde solution (Acros
organics, NJ, USA) then, the right maxilla was removed.
The obtained pieces were postfixed in 4% paraformaldehyde
solution, demineralized with 1% EDTA (Merck, Darmstadt,
Germany) and crioprotected with sucrose (Merck, Darmstadt,
Germany). The pieces were longitudinally sectioned through
the long axis of the alveolar process with a cryostat (Micron
Zeiss, Berlin, Germany) in order to obtain slices with 14 mm
thickness, that were mounted in previously gelatinized
slides.
2.5. Immunohistochemistry reaction
For the immunohistochemistry reactions, primary antibodies
anti TRAP, anti OPG and anti RANKL (Goat anti trap polyclonal,
Goat anti opg polyclonal; Goat anti rankl polyclonal – Santa
Cruz, CA, USA) and the biotinylated donkey anti goat
antibodies (Biotin-SP-AffiniPure donkey anti goat IgG-Jackson
Immunoresearch Laboratories, West Grove, PA, USA) was the
secondary antibody; the immunohistochemistry reaction
signal was amplified with the Avidin–Biotin system (Kit ABC
Vectastain Elite ABC, Vector Laboratories, Burlingame, CA,
USA) and the reaction was revealed using diaminobenzidine
(DAB – Sigma, Saint Louis, MO, USA) as the cromogen.
The analysis of the data was realized in a semi-quantitative
manner, the scores presented a variation from ‘‘’’ for no
labelling to ‘‘+, ++ and +++’’ to less, moderate and intense
labellings, respectively.
3. Results
As described in previous studies from our lab,11,12 estrous
cycle was monitored and OVX/O and OVX/RLX group
presented diestrus smear, atrophied uterine horns and lower
plasmatic concentration of estradiol. In contrast, the animals
submitted to sham surgery presented the four regular stages
of the estrous cycle, and the animals of group OVX/E2
presented enucleated cornified cells.
For all experimental groups, positive immunolabelling for
OPG and RANKL protein were visualized in cells of connective
tissue, osteoblasts around the trabeculae bone and in
osteocytes aprisioned in the bone tissue formed during the
alveolar healing process. TRAP protein was observed in
osteoclasts present around the alveolar walls and close to
the neoformed trabeculae bone.
At 7 postoperative days, besides the great amount of
haemosiderin, it was observed discrete RANKL immunolabel-
ling in osteoblasts around trabeculae bone and osteocytes of
the middle third (Fig. 1). Fibroblasts of the connective tissue
presented moderate immunolabelling of OPG protein (Fig. 2).
OVX/O group presented the highest immunolabelling for OPG
and RANKL protein than the other groups. TRAP immunola-
belling were not visualized in the middle third, only a discrete
labelling in the borders of the dental socket with no significant
difference between the groups (Fig. 3).
Fig. 1 – RANKL immunolabelling at 7, 14, 21, 28 and 42 days post-extraction in animals of sham, OVX/O, OVX/E2 and OVX/
RLX groups.
Fig. 2 – Osteoprotegerin immunolabelling at 7, 14, 21, 28 and 42 days post-extraction in animals of sham, OVX/O, OVX/E2
and OVX/RLX groups.
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Fig. 3 – TRAP immunolabelling at 7, 14, 21, 28 and 42 days post-extraction in animals of sham, OVX/O, OVX/E2 and OVX/RLX
groups.
Table 1 – Scores from the semi-quantitative manner, the
scores presented a variation from ‘‘S’’ for no labelling to
‘‘+, ++ and +++’’ to less, moderate and intense labellings,
respectively.
OPG RANKL TRAP
7 Days
SHAM ++ + +
OVX/O +++ ++ +
OVX/E2 ++ + +
OVX/RLX ++ + +
14 Days
SHAM ++ + +
OVX/O ++ ++ +++
OVX/E2 + + ++
OVX/RLX ++ + +
21 Days
SHAM ++ ++ +
OVX/O + +++ +++
OVX/E2 ++ ++ ++
OVX/RLX +++ ++ +
28 Days
SHAM ++ ++ +
OVX/O + +++ +++
OVX/E2 + ++ ++
OVX/RLX ++ + 
42 Days
SHAM   +
OVX/O  +++ ++
OVX/E2  ++ +
OVX/RLX ++  
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nolabelling (Fig. 1) similar to the previous period of all groups.
Sham and OVX/RLX groups showed similar OPG immunola-
belling (Fig. 2) compared to the previous analysed period,
whilst OVX/O and OVX/E2 showed a decreasing of OPG
immunolabelling. No background labelling with haemosiderin
was observed which facilitates the visualization of the area.
OVX/O group showed intense TRAP immunolabelling, moder-
ate for OVX/E2 group and discrete for sham and OVX/RLX
groups (Fig. 3).
At 21 postoperative days, OVX/O group showed a decreas-
ing OPG immunolabelling whilst it was increased for OVX/RLX
group compared to the previous period (Fig. 2). Additionally, an
increasing of RANKL immunolabelling was observed for all
experimental groups (Fig. 1). These findings suggest an
increasing in the cellular activity of bone remodelling process
in order to form bone tissue in the presence of raloxifene.
Considering TRAP immunolabelling, OVX/O group showed an
intense expression, OVX/E2 group showed a moderate
expression whilst sham and OVX/RLX showed a discrete
expression, similar to previous analysed period (Fig. 3).
At 28 and 42 postoperative days, OVX/O group showed a
decreasing in the OPG immunolabelling (Fig. 2), as well as a
significant increase in RANKL immunolabelling (Fig. 1). OVX/E2
group started to show a decreasing in OPG immunolabelling for
osteoblasts and osteocytes. OVX/O group presented expressive
labelling against RANKL. Raloxifene administration caused a
reduction in RANKL immunolabelling at 28 days and absence
immunolabelling at 42 days. TRAP immunolabelling was kept
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and reduced for the other groups, primarily for the OVX/RLX
group (Fig. 3) (Table 1).
4. Discussion
Oestrogen deficiency systemically affects bone remodelling
through OPG/RANKL signalisation during the events that
modulates osteoclasts cellular differentiation and lympho-
cytes development. In the experiments realized in our
laboratory, the osteoprotective effect of oestrogen in inhibits
bone resorption is confirmed after treating OVX rats with 17b-
estradiol. Which increased bone mass in the middle third of
the alveolar bone, however the action of raloxifene was not as
pronounced as E2.11,12
The intense immunolabelling for RANKL and TRAP
observed in OVX animals showed the signalling action of
the members of the tumour necrosis factor (RANKL) on
osteoclastic responses (TRAP). The oestrogen deficiency
following ovariectomy leds to a high bone turnover during
the alveolar healing process after tooth extraction whilst,
oestrogen and raloxifene treatments led to bone formation.
However TRAP expression at 28 and 42 days post-extraction in
OVX animals treated with raloxifene was very low, whilst this
expression was more expressive in OVX animals treated with
oestrogen. Our results suggest that raloxifene treatment may
compensate the changes induced by ovariectomy reducing the
number of pre-osteoclasts and mature osteoclasts.
Studies have shown that oestrogen deficiency leads to an
increase of osteocytes apoptosis in human beings13 and in
female rats14 and the osteocytes apoptosis can be reverted
through oestrogen replacement therapy14,15 or through ralox-
ifene therapy.16 Studies have suggested an autocrine mecha-
nism, through a Fas ligand (FasL), in which oestrogen-induced
osteoclast apoptosis17 and a paracrine mechanism in which
oestrogen affects osteoclast survival through FasL upregula-
tion in osteoblast cells leading to pre-osteoclasts apoptosis,18
this may explain the osteoprotective function of oestrogen as
well as of SERMs. However, Kawamoto et al.19 evaluated the
effects of oestrogen deficiency state in osteoclastogenesis of
the periodontal tissue at 7 postoperative days and did not find
any difference in the number of osteoclasts between oestro-
gen replacement therapy and sham groups. The authors also
observed a significant increase of TRAP expression at 14
postoperative days on OVX group compared to the others,
these finding are in agreement to our findings.
The increasing of OPG expression at 7 postoperative days
observed on OVX/O group suggests a transient increase in the
osteoblastogenesis during the initial step of the alveolar
wound healing process. This finding was also observed by
Miyazaki et al.20 Changes in bone formation marker (OPG)
were transient whilst changes in bone resorption markers
(RANKL and TRAP) were constant. These results were
confirmed by the immunohistochemistry of OPG protein,
where the increase in the osteoblast cells was only transient
during the initial step of the alveolar wound healing in OVX
rats (7 postoperative days), whilst the increase in the
osteoclastic differentiation was constant throughout the
experiment.Our findings suggest that raloxifene therapy reduces
osteoblastic cells apoptosis and, probably, acts blocking the
formation of osteoclasts brush borders more efficient than
estradiol therapy. As the literature shows controversial
findings,21–28 this findings are less discussed maybe due to
the limited number of scientific papers that compare both
therapies.
Studies has shown that raloxifene therapy, in a dose
dependent manner, protects bone tissue blocking osteoclas-
togenesis, mature osteoclasts activation and their surviv-
al.27,29 Our findings indicate that raloxifene therapy
compensates OVX statement by reducing the number of
pre-osteoclasts and mature osteoclasts. As showed in this
study in which OVX/RLX group presented a minor TRAP
labelling at 28 postoperative days and an absence of TRAP
labelling at 42 postoperative days compared to sham and OVX/
E2 groups. Also we observed a minor RANKL expression on
OVX/RLX group at 28 and 42 postoperative days compared to
OVX/E2 group.
The intense RANKL immunolabelling was more significant
at 28 and 42 postoperative days on OVX group. This finding is
in agreement to our previous studies in which we observed the
least amount of bone formation at the same period and same
group.11,12 An important observation is the intense expression
of RANKL and TRAP protein observed in some experimental
groups emphasizing previous evidences4,5,19,27–29 that suggest
the signalling role of the tumoural necrosis factor members
(RANKL) on the osteoclastic responses (TRAP). Considering the
signal cellular responses, raloxifene therapy decreased RANKL
immunolabelling and increased OPG immunolabelling, con-
sequently decreasing TRAP. This finding is confirmed by
previous studies4,5,19,27–29 that show the role of raloxifene
therapy in protecting bone tissue that brings an important
therapeutic option to keep bone tissue homeostasis.
Studies of Cheung et al.30 in bone marrow cloned cells
cultures (HCC1) with osteoblastic characteristics and primary
human osteoblasts (HOB) showed a significant reduction in
RANKL expression in cells treated with raloxifene whilst
oestrogen treatment did not show significant changes. As
RANKL/OPG balance showed a reduction on OVX/RLX group
compared to OVX/E2 group. Another important finding of our
study in which raloxifene acts is increasing OPG expression. A
result also observed by Viereck et al.,31 Messalli et al.32 and
Michael et al.33 These findings suggest that the raloxifene and
oestrogen present different mechanisms of action in the
expression of OPG, RANKL and TRAP. Furthermore, oestrogen
and SERMs present different clinical profile, differently
modulating ERa and Erb transcription activities.23,34–36 In
recent study realized by Yan et al.,37 with OPG knockout
female rats, the authors observed an increase in bone
trabecular area, bone mineral density and bone resistance
after raloxifene therapy as well as a reduction in osteoclasts
number and RANKL transcription, suggesting that raloxifene
mechanism of action do not depend on OPG protein.
SERMs preserve the positive effects of oestrogen on bone
tissue without adverse effects in uterine and breast tissues.38
Whilst raloxifene has shown protective action of osteocytes
apoptosis induction caused by OVX,24,29,39 the molecular
mechanism of this protection remains unknown. Structurally
different from oestrogen, raloxifene retain a cyclohexane
a r c h i v e s o f o r a l b i o l o g y 5 6 ( 2 0 1 1 ) 9 8 4 – 9 9 0 989hydroxyl group C3 which may potentially facilitate its
antioxidant action.
More studies are necessary to better evaluate the biological
mechanisms in which raloxifene acts. Even though, our
experiments have shown an important participation of
tumoural necrosis factor in signalising osteoclastic activity
inhibition. RANKL immunolabelling reduction and OPG
immunolabelling increasing and its consequent reduction of
TRAP immunolabelling observed on OVX/RLX group shows the
role of raloxifene therapy in protecting bone tissue that brings
an important therapeutic option to keep bone tissue homeo-
stasis.
5. Conclusion
Oestrogen deficiency induces osteoclastogenesis in the alveo-
lar healing process. Quantitative changes in the osteoclastic
activity could be prevented through the raloxifene therapy.
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